Actively Recruiting
Weight Management Study of Macupatide and Eloralintide Alone or Combined in Adults with Overweight or Obesity Without Type 2 Diabetes
Led by Eli Lilly and Company · Updated on 2026-10-08
400
Participants Needed
40
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effectiveness and safety of macupatide and eloralintide, alone or combined, in managing weight among adults who are overweight or obese but do not have type 2 diabetes. The study is conducted under a master protocol and seeks to understand how these treatments affect body weight changes over time. Participants are randomly assigned to one of several groups to receive macupatide, eloralintide, their combination, or a placebo. All treatments are given through subcutaneous injections. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The main treatment period lasts about 36 weeks, with additional assessments extending to around 64 weeks. During the study, participants will be closely monitored through various visits to assess changes in body weight and body mass index. Researchers will measure the percentage change in body weight from the start of the study to week 36 and beyond. Safety and adherence will also be tracked throughout the study, which lasts approximately 64 weeks in total.
CONDITIONS
Brief Title
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here